PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 17, 2026ACS Nano2 citations

Aptamer-Driven DNA Framework Switches for Clearing Programmed Cell Death-Ligand 1 Positive Extracellular Vesicles via Macrophage Recruitment

View Full Paper
LZLiyan ZhengJZJingchen ZhangPLPanmin Lei

Key Points

  • The central aim is to design a synthetic DNA framework that improves the immune system's ability to clear PD-L1 positive extracellular vesicles.
  • Development of a DNA framework switch (MJ5C-Man6-DF) targeting PD-L1 positive EVs.
  • Utilization of a recognition-then-recruitment mechanism to activate macrophages.
  • Evaluation of switch performance in vivo.
  • The aptamer-driven DF switch enhanced αPD-L1 therapy efficacy by 90.7%.
  • T cell activation increased by 55% following application of the DNA switch.
  • Demonstrated exceptional stability and specificity in targeting PD-L1 positive EVs.

Abstract

The immune system employs molecular switches to maintain dynamic homeostasis, yet malignant cells often learn from these natural switches and ultimately evade immune surveillance, leading to immune tolerance and tumor deterioration. Chemically synthetic switches designed to redirect immune signaling pathways are highly desired for reversing this pathological trajectory but are rarely reported. Herein, we develop a synthetic DNA framework (DF) switch that reprograms macrophage-mediated immune clearance of Programmed Cell Death-Ligand 1 Positive (PD-L1+) extracellular vesicles (EVs) in vivo. This synthetic switch is composed of a ligand (Man6)-terminated PD-L1-targeting aptamer (MJ5C) and a DF, termed hereinafter as MJ5C-Man6-DF, which operates through a recognition-then-recruitment mechanism. Thus, in the "off state", MJ5C stably resides within the DF, retaining Man6 in its inner cavity. However, upon target recognition, MJ5C switches to the "on state" and binds to PD-L1+ EVs, conferring conformational changes that allow coating of its terminal Man6 on EVs. Man6-coated EVs then recruit macrophages via the membrane receptor CD206, enabling efficient phagocytosis. MJ5C-Man6-DFs were shown to perform with exceptional stability and specificity, augmenting αPD-L1 therapy by 90.7% while boosting T cell activation by 55% in vivo. Therefore, our aptamer-driven DF switch provides a strategy for precise immune reprogramming in the field of DNA-based molecular engineering.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zheng et al. (2026) studied this question.

synapsesocial.com/papers/69b8ef52deb47d591b8c55c4https://doi.org/10.1021/acsnano.5c19052
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Apoptotic Extracellular Vesicles Ameliorate Multiple Myeloma by Restoring Fas-Mediated Apoptosis2021 · 140 citations
  2. 2Harnessing DNA for Immunotherapy: Cancer, Infectious Diseases, and Beyond2022 · 22 citations
  3. 3Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor2019 · 14 citations
  4. 4MicroRNAs as Molecular Switches in Macrophage Activation2019 · 182 citations
  5. 5The cancer metabolic reprogramming and immune response2021 · 1,356 citations